Remember when you thought you understood the stock market? Yeah, forget that. Regencell Bioscience (NASDAQ:RGC) just threw a 17,000% curveball at everyone’s assumptions about how stocks are supposed to work.
Let’s set the scene: It’s 2025, and somewhere in Hong Kong, a biotech company with literally zero dollars in revenue—not a penny, not a dime—somehow convinced the market it’s worth $11 billion. If that sounds insane, that’s because it kind of is.
Here’s the kicker: Regencell has been around since 2021 and hasn’t made a single dollar from actual sales. The company’s entire business model is basically “we’re researching traditional Chinese medicine for ADHD and autism, trust us bro.” And yet, the stock went absolutely bonkers, climbing from pennies to $595 per share before a 38-for-1 stock split brought it down to $16, then back up to $23.
So what actually happened? The perfect storm of chaos. First, Regencell has what’s called a “low float”—meaning almost nobody can actually buy the stock because the founder owns 88.6% of shares. That’s like trying to buy a house when the owner won’t sell. When supply is that tight, even small buying pressure sends prices through the roof.
Then came the algorithmic trading bots. These AI-powered traders spotted the low float and flagged it like a golden ticket. Add some social media buzz about the promise of treating ADHD and autism with traditional Chinese medicine, sprinkle in some early trial hype, and boom—you’ve got a perfect recipe for a stock explosion.
The 38-for-1 split made the stock cheaper to buy, which attracted even more retail investors. Suddenly, everyone wanted a piece of this “miracle” stock. The price rocketed to $70 per share post-split before crashing back down. It’s been bouncing around ever since.
But here’s where it gets spicy: The U.S. Department of Justice is investigating the company for suspicious trading activity. Yeah, that’s right—while everyone’s celebrating their gains, the feds are asking questions about what the heck is actually going on.
The bottom line? Regencell is a masterclass in why you should be careful what you wish for. Yes, some people made life-changing money. But this stock has no revenue, no earnings, no analyst coverage, and a federal investigation hanging over its head. It’s basically the financial equivalent of buying a lottery ticket and winning—except the lottery ticket is also on fire.
If you’re thinking about jumping in, remember: a 17,000% gain is great until it’s a 99% loss. This isn’t investing; it’s gambling with extra steps.
